FI70672C - Foerfarande foer rening av en liposomsuspension - Google Patents
Foerfarande foer rening av en liposomsuspension Download PDFInfo
- Publication number
- FI70672C FI70672C FI800151A FI800151A FI70672C FI 70672 C FI70672 C FI 70672C FI 800151 A FI800151 A FI 800151A FI 800151 A FI800151 A FI 800151A FI 70672 C FI70672 C FI 70672C
- Authority
- FI
- Finland
- Prior art keywords
- suspension
- resins
- resin
- drug
- groups
- Prior art date
Links
- 239000000725 suspension Substances 0.000 claims description 40
- 239000002502 liposome Substances 0.000 claims description 36
- 239000011347 resin Substances 0.000 claims description 35
- 229920005989 resin Polymers 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003456 ion exchange resin Substances 0.000 claims description 6
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002952 polymeric resin Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- -1 for example Chemical compound 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical group CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012609 strong anion exchange resin Substances 0.000 claims description 2
- 125000001174 sulfone group Chemical group 0.000 claims description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012610 weak anion exchange resin Substances 0.000 claims description 2
- 239000012608 weak cation exchange resin Substances 0.000 claims description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229920001568 phenolic resin Polymers 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000008344 egg yolk phospholipid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- ZXHDFKAHCABVAF-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CC1=CC=CC=C1C=C ZXHDFKAHCABVAF-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GXKYUEKYNXVQRY-UHFFFAOYSA-N C1(=CC=CC=C1)C1=C(C=CC=C1)C1=CC=CC=C1.C=CC1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)C1=C(C=CC=C1)C1=CC=CC=C1.C=CC1=CC=CC=C1 GXKYUEKYNXVQRY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- XLLNINGEDIOQGQ-UHFFFAOYSA-N [acetyloxy(hydroxy)phosphoryl] acetate Chemical compound CC(=O)OP(O)(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1943479 | 1979-01-19 | ||
| IT19434/79A IT1110989B (it) | 1979-01-19 | 1979-01-19 | Forme farmaceutiche costitutite da liposomi e procedimenti relativi |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI800151A7 FI800151A7 (fi) | 1980-07-20 |
| FI70672B FI70672B (fi) | 1986-06-26 |
| FI70672C true FI70672C (fi) | 1986-10-06 |
Family
ID=11157905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI800151A FI70672C (fi) | 1979-01-19 | 1980-01-17 | Foerfarande foer rening av en liposomsuspension |
Country Status (21)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU184141B (en) * | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2553002B1 (fr) * | 1983-10-06 | 1992-03-27 | Centre Nat Rech Scient | Procede perfectionne d'obtention de liposomes unilamellaires de diametres eleves, leur application pharmacologique pour l'encapsulage d'un principe actif en vue de son administration extemporanee et dispositif correspondant |
| CA1270198C (en) * | 1984-08-08 | 1990-06-12 | Marcel B Bally | ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES |
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4755388A (en) * | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
| IL79114A (en) * | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
| US6406713B1 (en) * | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| EP0555229B1 (en) * | 1990-07-31 | 1996-06-05 | The Liposome Company, Inc. | Accumulation of amino acids and peptides into liposomes |
| DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
| DE4107152C2 (de) * | 1991-03-06 | 1994-03-24 | Gregor Cevc | Präparate zur nichtinvasiven Verabreichung von Antidiabetica |
| JPH04127874U (ja) * | 1991-05-13 | 1992-11-20 | 株式会社新潟鐵工所 | コンクリートポンプ用輸送管の圧送音緩和装置 |
| JPH04134673U (ja) * | 1991-06-07 | 1992-12-15 | 株式会社フジタ | コンクリート圧送圧変動防止装置 |
| AU676906B2 (en) * | 1993-04-02 | 1997-03-27 | Transave, Inc. | Method of producing liposomes |
| IT1270678B (it) * | 1994-10-20 | 1997-05-07 | Bayer Ag | Liposomi al chetoprofen |
| DE19639811A1 (de) * | 1996-09-27 | 1998-04-02 | Artur Herzog Dr Mesmer | Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln |
| JP4283355B2 (ja) * | 1997-11-10 | 2009-06-24 | 久光製薬株式会社 | 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物 |
| CN1278738A (zh) * | 1997-11-10 | 2001-01-03 | 久光制药株式会社 | 药剂用缓释和含有该缓释剂的缓释性药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2249552A1 (de) * | 1971-10-12 | 1973-05-30 | Inchema S A | Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen |
| JPS5126213A (ja) * | 1974-08-21 | 1976-03-04 | Tanabe Seiyaku Co | Johoseibiryushiseizaino seiho |
| US4131815A (en) * | 1977-02-23 | 1978-12-26 | Oceanography International Corporation | Solid piezoelectric sand detection probes |
| GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| NL7809709A (nl) * | 1977-09-30 | 1979-04-03 | Farmaceutici Italia | Werkwijze voor het bereiden van injecteerbare liposomen |
-
1979
- 1979-01-19 IT IT19434/79A patent/IT1110989B/it active
-
1980
- 1980-01-09 NL NL8000139A patent/NL8000139A/nl not_active Application Discontinuation
- 1980-01-14 YU YU81/80A patent/YU44003B/xx unknown
- 1980-01-14 JP JP219280A patent/JPS55100313A/ja active Granted
- 1980-01-14 AU AU54581/80A patent/AU536823B2/en not_active Ceased
- 1980-01-14 IL IL59120A patent/IL59120A/xx unknown
- 1980-01-15 FR FR808000801A patent/FR2446635B1/fr not_active Expired
- 1980-01-15 AT AT0019380A patent/AT370623B/de not_active IP Right Cessation
- 1980-01-15 CA CA000343663A patent/CA1148470A/en not_active Expired
- 1980-01-15 CS CS80309A patent/CS227010B2/cs unknown
- 1980-01-16 IE IE91/80A patent/IE49141B1/en unknown
- 1980-01-16 ZA ZA00800269A patent/ZA80269B/xx unknown
- 1980-01-17 GB GB8001545A patent/GB2041871B/en not_active Expired
- 1980-01-17 SU SU802869298A patent/SU1367839A3/ru active
- 1980-01-17 CH CH370/80A patent/CH648205A5/de not_active IP Right Cessation
- 1980-01-17 HU HU8097A patent/HU184714B/hu not_active IP Right Cessation
- 1980-01-17 FI FI800151A patent/FI70672C/fi not_active IP Right Cessation
- 1980-01-18 SE SE8000443A patent/SE445171B/sv not_active IP Right Cessation
- 1980-01-18 DE DE19803001842 patent/DE3001842A1/de active Granted
- 1980-01-18 BE BE0/199021A patent/BE881225A/fr not_active IP Right Cessation
- 1980-01-18 DK DK022380A patent/DK157060C/da not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI70672C (fi) | Foerfarande foer rening av en liposomsuspension | |
| US4460577A (en) | Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same | |
| CA1143656A (en) | Liposome including active substance | |
| JPH0545568B2 (enrdf_load_stackoverflow) | ||
| JPH0468284B2 (enrdf_load_stackoverflow) | ||
| JPS59173133A (ja) | リポゾ−ム類の製造法および該方法によつて得られる生成物 | |
| JP2517094B2 (ja) | リン脂質組成物 | |
| Tokutomi et al. | Proton-induced phase separation in phosphatidylserine/phosphatidylcholine membranes | |
| JPS6111931B2 (enrdf_load_stackoverflow) | ||
| Ohki et al. | Monovalent cation-induced phospholipid vesicle aggregation: effect of ion binding | |
| AU2010287391B2 (en) | Particle composition and medicinal composition comprising same | |
| JPH03502576A (ja) | リポソームへのアフィニティ結合による精製 | |
| Zakharov et al. | Oligomeric structure of brain abundant proteins GAP-43 and BASP1 | |
| EP1325334B1 (de) | Verfahren zur immobilisierung von lipidschichten | |
| CA1116518A (en) | Method for purifying a liposomic suspension | |
| WO2011037094A1 (ja) | 分離方法 | |
| EP0783295A1 (en) | Method of producing a lyophilized liposome product | |
| Kramer et al. | Rapid transmembrane movement of phosphatidylcholine in small unilamellar lipid vesicles formed by detergent removal | |
| Jonas | Phosphatidyl choline interaction with bovine serum albumin: Effect of the physical state of the lipid on protein-lipid complex formation | |
| WO2005092389A1 (ja) | 複合粒子および被覆複合粒子 | |
| EP0245985B1 (en) | Liquid-liquid extraction method using particulate polymeric adsorbent | |
| JP3399009B2 (ja) | リポソームの製造方法 | |
| JPH01290634A (ja) | インターフェロン含有リポソーム製剤およびその製造法 | |
| JPH0679104A (ja) | エンドトキシンの除去方法 | |
| Uda et al. | Proteolipid of bovine brain white matter: relationship between phospholipid and protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: FARMITALIA CARLO ERBA S.R.L. |